Literature DB >> 47261

A staging system for hepatocellular carcinoma: prognostic factors in Ugandan patients.

A Primack, C L Vogel, S K Kyalwazi, J L Ziegler, R Simon, P P Anthony.   

Abstract

A staging scheme for hepatocellular carcinoma was presented at an International Symposium on Liver Cancer in Kampala, Uganda in 1971. Historical, clinical, and laboratory aspects of that staging scheme were examined for prognostic significance in 72 untreated patients with this disease studied at the Uganda Cancer Institute. The median survival for the entire group was 1 month. The presence of a serum bilirubin concentration of greater than 2 mg/100 ml or weight loss greater than 25 percent of body weight were the poorest prognostic features. Other factors with prognostic significance were visible abdominal collateral circulation, ascites, tumor differentiation, and serum levels of alkaline phosphatase, SGOT, alpha fetoprotein, and proline hydroxylase. A modified staging scheme is presented which defines three prognostically different groups of Ugandan patients. It is hoped this staging scheme will serve as a stimulus for analysis of similar prognostic features in other populations of patients with hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 47261     DOI: 10.1002/1097-0142(197505)35:5<1357::aid-cncr2820350518>3.0.co;2-8

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

Review 1.  Advances in neoplastic disease of the liver and biliary tract.

Authors:  P J Johnson; M L Wilkinson; J Karani
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

2.  Edmondson-Steiner grading increases the predictive efficiency of TNM staging for long-term survival of patients with hepatocellular carcinoma after curative resection.

Authors:  Li Zhou; Jing-An Rui; Da-Xiong Ye; Shao-Bin Wang; Shu-Guang Chen; Qiang Qu
Journal:  World J Surg       Date:  2008-08       Impact factor: 3.352

Review 3.  Geographic heterogeneity of hepatocellular carcinoma.

Authors:  K Okuda
Journal:  Gastroenterol Jpn       Date:  1990-12

4.  Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization and analysis of prognostic factors.

Authors:  M Y Hsieh; W Y Chang; L Y Wang; S C Chen; W L Chuang; S N Lu; D K Wu
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Evaluation of conservative therapeutic modalities for hepatocellular carcinoma--analysis of 206 cases.

Authors:  K Ando
Journal:  Gastroenterol Jpn       Date:  1984-10

6.  Antigenic characterization of human hepatocellular carcinoma. Development of in vitro and in vivo immunoassays that use monoclonal antibodies.

Authors:  R I Carlson; E Ben-Porath; D Shouval; W Strauss; K J Isselbacher; J R Wands
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

7.  Human prolyl hydroxylase. Purification, radioimmunoassay and clinical studies in liver diseases.

Authors:  Y Nagai; H Oka
Journal:  Gastroenterol Jpn       Date:  1985-02

8.  Combined cis-platinum and alpha interferon therapy of advanced hepatocellular carcinoma.

Authors:  S K Ji; N H Park; H M Choi; Y W Kim; S H Lee; K H Lee; S Y Ahn; S U Lee; B H Han; B C Park
Journal:  Korean J Intern Med       Date:  1996-01       Impact factor: 2.884

9.  Natural history and prognostic factors of primary hepatocellular carcinoma: study of 70 untreated patients.

Authors:  U B Kim; C J Doo; S H Baek; J H Kim; H B Lee; S K Park; J H Byun
Journal:  Korean J Intern Med       Date:  1989-07       Impact factor: 2.884

10.  Relationship between serum alpha-foetoprotein, cirrhosis and survival in hepatocellular carcinoma.

Authors:  P J Johnson; W M Melia; M K Palmer; B Portmann; R Williams
Journal:  Br J Cancer       Date:  1981-10       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.